STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNYA
  4. [8-K] Tenaya Therapeutics, Inc. Reports Material Event

Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. has terminated its lease for the Genetic Medicines Manufacturing Center in Union City, California. The lease covered approximately 94,046 rentable square feet and was originally set to run until July 2031 but will now end on August 31, 2026.

To exit the lease, Tenaya will forfeit a $1,750,000 security deposit and pay a one-time lease termination fee of about $294,200. The facility was decommissioned in 2025 to reduce costs, and existing TN-201 and TN-401 inventory is expected to support ongoing clinical trials.

The company plans to keep its internal process and assay development know-how while transferring its AAV manufacturing process to a contract development manufacturing organization with global capabilities for potential future late-stage development or commercial launch of TN-201 and TN-401.

Positive

  • None.

Negative

  • None.

Insights

Tenaya trades a dedicated in-house plant for lower-commitment outsourced manufacturing.

Tenaya is exiting a long-dated lease on its Union City Genetic Medicines Manufacturing Center, which was already decommissioned in 2025 to cut costs. The lease, once running to July 2031, will now end on August 31, 2026, shrinking long-term facilities obligations.

Economically, Tenaya forfeits a $1,750,000 security deposit and pays about $294,200 as a termination fee. That is a defined, one-time charge in exchange for eliminating several additional years of lease commitments on 94,046 rentable square feet.

Operationally, the company keeps its process and assay development expertise and plans to transfer its AAV manufacturing to a contract development manufacturing organization with global capabilities. Future disclosures in company filings can show how this outsourced model supports late-stage development and any potential commercial launch of TN-201 and TN-401.

Item 1.02 Termination of a Material Definitive Agreement Business
A significant contract was terminated, which may affect business operations or revenue.
Security deposit forfeited $1,750,000 Consideration for Union City lease termination
Lease termination fee approximately $294,200 One-time payment to terminate lease
Facility size 94,046 rentable square feet Genetic Medicines Manufacturing Center in Union City
New lease end date August 31, 2026 Revised termination date for Union City lease
Original lease expiry July 2031 Initial scheduled expiration of Union City lease
Lease Termination Agreement financial
"On June 29, 2026, Tenaya Therapeutics, Inc. entered into a Lease Termination Agreement with Terreno Park Union City LLC"
Genetic Medicines Manufacturing Center technical
"The space served as the Company’s Genetic Medicines Manufacturing Center (the “GMMC Facility”), which the Company decommissioned in 2025"
contract development manufacturing organization technical
"plans to transfer its AAV manufacturing process to a contract development manufacturing organization with global capabilities"
A contract development and manufacturing organization (CDMO) is a business that other firms hire to design, test and produce drugs, biologics or medical products, handling tasks from early formulation to large‑scale manufacturing. For investors, a CDMO is like a specialist factory and consultant combined: it lets developers bring products to market without building their own plants, so a CDMO’s sales and margins reflect demand for outsourced drug development and production and can signal industry health.
Emerging growth company regulatory
"Emerging growth company Item 1.02 Termination of a Material Definitive Agreement."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Material Definitive Agreement regulatory
"Item 1.02 Termination of a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What lease did Tenaya Therapeutics (TNYA) terminate in this 8-K?
Tenaya terminated its lease for approximately 94,046 rentable square feet at 33498 Central Avenue, Union City, California. The space housed its Genetic Medicines Manufacturing Center, which was decommissioned in 2025 as part of efforts to reduce operating costs.

When does the terminated Tenaya Therapeutics (TNYA) lease now end?
The lease will now terminate on August 31, 2026. It was originally scheduled to expire in July 2031, so this agreement shortens Tenaya’s long-term commitment to the Union City Genetic Medicines Manufacturing Center location by several years.

What costs will Tenaya Therapeutics (TNYA) incur to terminate the lease?
Tenaya will forfeit its $1,750,000 security deposit and pay a one-time lease termination fee of approximately $294,200. These charges represent the consideration agreed with the landlord, Terreno Park Union City LLC, for ending the lease early.

Why can Tenaya Therapeutics (TNYA) close the Genetic Medicines Manufacturing Center?
Closure of the Genetic Medicines Manufacturing Center is possible because Tenaya has sufficient inventory of TN-201 and TN-401 to support ongoing clinical trials. This inventory reduces reliance on the Union City manufacturing facility for current study needs.

How will Tenaya Therapeutics (TNYA) handle AAV manufacturing after this lease termination?
Tenaya plans to retain its internal process and assay development know-how while transferring its AAV manufacturing process to a contract development manufacturing organization with global capabilities. This arrangement is intended to support future late-stage development or potential commercial launch of TN-201 and TN-401.

Who is the landlord in Tenaya Therapeutics’ (TNYA) lease termination agreement?
The lease termination agreement is with Terreno Park Union City LLC. This entity is the landlord for the Union City facility at 33498 Central Avenue that housed Tenaya’s Genetic Medicines Manufacturing Center before it was decommissioned in 2025.
0001858848false00018588482026-06-292026-06-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2026

 

 

Tenaya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40656

81-3789973

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

171 Oyster Point Boulevard

Suite 500

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 825-6990

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TNYA

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.02 Termination of a Material Definitive Agreement.

On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenue, Union City, California 94587. The space served as the Company’s Genetic Medicines Manufacturing Center (the “GMMC Facility”), which the Company decommissioned in 2025 to reduce costs. Closure of the GMMC Facility is possible due to available inventory of TN-201 and TN-401 to support its ongoing clinical trials. The lease was originally scheduled to expire in July 2031, and will now terminate on August 31, 2026. As consideration for the lease termination, the Company agreed to forfeit its $1,750,000 security deposit and pay a one-time lease termination fee of approximately $294,200.

The Company has retained its internal process and assay development know-how and plans to transfer its AAV manufacturing process to a contract development manufacturing organization with global capabilities in anticipation of future late-stage development and/or commercial launch of TN-201 and/or TN-401.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

TENAYA THERAPEUTICS, INC.

 

 

 

By:

 

 

/s/ Jennifer Drimmer Rokovich

 

 

 

 

Jennifer Drimmer Rokovich

 

 

 

 

General Counsel and Secretary

Date: July 2, 2026

 

 

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Other Documents